Want to see MLSS full AI Analyst Report?
MLSS Stock Chart & Stats
$0.39
$0.01(3.13%)
At close: 4:00 PM EDT
$0.39
$0.01(3.13%)
Day’s Range― - ―
52-Week Range$0.22 - $0.68
Previous Close$0.4
Volume145.61K
Average Volume (3M)172.66K
Market Cap
$35.29M
Enterprise Value$24.28
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$985.35K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 18, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding88,449,410
10 Day Avg. Volume233,274
30 Day Avg. Volume172,658
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside156.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$10.06M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA sustained ~72% gross margin indicates the company’s products have strong unit economics and pricing power versus direct costs. High product margins create durable room to cover fixed costs, support reinvestment into sales or R&D, and improve the path to operating leverage as volume grows over the next 2–6 months.
Meaningful Cost ReductionsA >30% year-over-year cut in operating expenses and a ~58% narrowing of operating loss show management’s ability to structurally lower fixed costs. Sustained expense discipline improves cash runway and makes breakeven achievable sooner, reducing reliance on frequent fundraising and strengthening long-term viability.
Early CompuFlo Commercial TractionDoubling of medical product revenue and active reimbursement filings signal initial commercial adoption and a pathway to scalable sales. Ongoing advisor partnerships, distributor expansion and reimbursement filings are structural enablers for durable growth if adoption and Medicare coding advance over coming quarters.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business consumes capital and needs external financing to operate. Even with recent improvements, persistent cash burn limits strategic flexibility, raises dilution risk, and demands sustained execution to convert margin and expense gains into positive cash generation.
Weak Revenue TrendA nearly 25% TTM revenue decline and ongoing deep operating losses indicate structural demand or execution gaps. Until the company reverses topline decline and demonstrates consistent revenue growth, fixed-cost absorption remains constrained and profitability targets may be elusive despite margin and cost improvements.
Reimbursement & Scale UncertaintyLong-term commercial success depends on securing durable reimbursement and clinician utilization. Medicare/MAC coding uncertainty and CompuFlo’s small absolute base create execution risk: delayed or unfavorable reimbursement timelines could slow adoption, limit pricing power, and constrain nonlinear revenue scaling.
Milestone Scientific News
MLSS FAQ
What was Milestone Scientific’s price range in the past 12 months?
Milestone Scientific lowest stock price was $0.22 and its highest was $0.68 in the past 12 months.
What is Milestone Scientific’s market cap?
Milestone Scientific’s market cap is $35.29M.
When is Milestone Scientific’s upcoming earnings report date?
Milestone Scientific’s upcoming earnings report date is Aug 18, 2026 which is in 12 days.
How were Milestone Scientific’s earnings last quarter?
Milestone Scientific released its earnings results on May 14, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Milestone Scientific overvalued?
According to Wall Street analysts Milestone Scientific’s price is currently Undervalued.
Does Milestone Scientific pay dividends?
Milestone Scientific does not currently pay dividends.
What is Milestone Scientific’s EPS estimate?
Milestone Scientific’s EPS estimate is -0.01.
How many shares outstanding does Milestone Scientific have?
Milestone Scientific has 88,449,410 shares outstanding.
What happened to Milestone Scientific’s price movement after its last earnings report?
Milestone Scientific reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.286%.
Which hedge fund is a major shareholder of Milestone Scientific?
Currently, no hedge funds are holding shares in MLSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Scientific Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.00 (156.41% Upside)
$1.00 (156.41% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.38%
Trailing 12-Months
Company Description
Milestone Scientific
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets. The company's operations are divided into two main segments: Dental and Medical. Within its Dental division, key products include CompuDent and the STA Single Tooth Anesthesia System, both instrumental for delivering local anesthetics across all dental procedures. For broader applications, the firm offers CompuFlo, a sophisticated computer-controlled system capable of delivering drugs, anesthetics, and other medicaments comfortably and precisely, as well as aspirating bodily fluids or prior injections. Complementing this, a disposable injection handpiece provides precise tactile control during administration. In the Medical segment, Milestone Scientific introduces the CompuFlo Epidural, a computer-guided anesthesia system designed for a variety of medical applications. Additionally, their CompuMed system is utilized in numerous specialized procedures, including plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics, among others. Headquartered in Livingston, New Jersey, Milestone Scientific Inc. was established in 1989.
MLSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously positive outlook: management delivered meaningful expense reductions (>$1.3M, >30% YoY) and materially narrowed operating and net losses (both improved ~58%), while early traction in CompuFlo (medical revenue up >100% and roughly $108k in Q1), strong digital lead generation (152 leads), >50 reimbursement claims submitted, expansion of distributor and ambassador programs, and a $2.15M financing bolster the growth case. Key near-term risks remain—flat overall revenue for the quarter, a $200k shipping disruption, modest gross margin decline, CompuFlo's small absolute revenue base, and dependence on Medicare/MAC reimbursement timing and utilization to unlock nonlinear growth. Given that the positive operational improvements, financing, and early commercial traction outweigh the execution and reimbursement risks at this stage, the overall sentiment is constructive but cautious.View all MLSS earnings summariesMLSS Stock 12 Month Forecast
Average Price Target
$1.00
▲(156.41% Upside)
Technical Analysis
Retractable Technologies
―
Precision Optics Corporation
―
Nephros
―
Femasys
―
NexGel Inc
―
Ownership Overview
10.06% Insiders
2.93% Mutual Funds
0.19% Other Institutional Investors
84.37% Public Companies and
Individual Investors